The Traderszone Network

27 May, 2014 by The TZ Newswire Staff Comments Off on Huge surge in spam emails pitching penny stocks

Huge surge in spam emails pitching penny stocks

Spam messages hyping penny stocks are multiplying, accounting for 16% of unwanted email in 2013, up from less than 1% the year before.
read more

27 May, 2014 by The TZ Newswire Staff Comments Off on Futures Movers: Oil pulls back as Ukraine concerns ease

Futures Movers: Oil pulls back as Ukraine concerns ease

Oil futures pull back from their highest close in five weeks following a successful election in Ukraine.
read more

27 May, 2014 by The TZ Newswire Staff Comments Off on GBP/USD extends decline to 1-week low at 1.6805; watch orders

GBP/USD extends decline to 1-week low at 1.6805; watch orders

FXStreet (San Francisco) – The Sterling is trading under pressure against the US Dollar following a…

For more information, read our latest forex news.

27 May, 2014 by The TZ Newswire Staff Comments Off on Chasing the Latin American retail consumer

Chasing the Latin American retail consumer

MercadoLibre is the eBay of Latin America. The founder talks about how he built the largest regional retailer.

27 May, 2014 by The TZ Newswire Staff Comments Off on United States Dallas Fed Manufacturing Business Index: 8 (May) vs previous 11.7

United States Dallas Fed Manufacturing Business Index: 8 (May) vs previous 11.7

FXStreet.com (Barcelona) For more information, read our latest forex news.

For more information, read our latest forex news.

27 May, 2014 by The TZ Newswire Staff Comments Off on This is a huge sign the markets aren’t healthy

This is a huge sign the markets aren’t healthy

The market is making new highs on the backs of fewer and fewer stocks. And, there may be other big problems as well.

27 May, 2014 by The TZ Newswire Staff Comments Off on Pfizer ponders next move after AstraZeneca bid rejection

Pfizer ponders next move after AstraZeneca bid rejection

Pfizer, the largest U.S, drugmaker, yesterday abandoned its effort to buy AstraZeneca for $117 billion, saying the public bid rejected by its London-based competitor represented “full value.”